Amgen Inc. AMGN.BA Stock
Amgen Inc. Price Chart
Amgen Inc. AMGN.BA Financial and Trading Overview
Amgen Inc. stock price | 9375.5 ARS |
Previous Close | 11130.5 ARS |
Open | 11326.5 ARS |
Bid | 11481 ARS x N/A |
Ask | 12000 ARS x N/A |
Day's Range | 11302 - 11636 ARS |
52 Week Range | 360.5 - 11636 ARS |
Volume | 1.04K ARS |
Avg. Volume | 0 ARS |
Market Cap | 33.51T ARS |
Beta (5Y Monthly) | 0.642957 |
PE Ratio (TTM) | 33.215706 |
EPS (TTM) | 54067.14 ARS |
Forward Dividend & Yield | 5.7 (1.58%) |
Ex-Dividend Date | May 17, 2023 |
1y Target Est | N/A |
AMGN.BA Valuation Measures
Enterprise Value | 165.23T ARS |
Trailing P/E | 33.215706 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1279.5117 |
Price/Book (mrq) | 32261.242 |
Enterprise Value/Revenue | 6309.027 |
Enterprise Value/EBITDA | 12592.092 |
Trading Information
Amgen Inc. Stock Price History
Beta (5Y Monthly) | 0.642957 |
52-Week Change | 0% |
S&P500 52-Week Change | 20.43% |
52 Week High | 11636 ARS |
52 Week Low | 360.5 ARS |
50-Day Moving Average | 360.5 ARS |
200-Day Moving Average | 360.5 ARS |
AMGN.BA Share Statistics
Avg. Volume (3 month) | 0 ARS |
Avg. Daily Volume (10-Days) | 0 ARS |
Shares Outstanding | 106.87M |
Float | 14.81B |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 7.95 |
Trailing Annual Dividend Yield | 0.071% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.0148 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 30.22% |
Operating Margin (ttm) | 36.83% |
Gross Margin | 74.93% |
EBITDA Margin | 50.10% |
Management Effectiveness
Return on Assets (ttm) | 8.15% |
Return on Equity (ttm) | 252.77% |
Income Statement
Revenue (ttm) | 26.19B ARS |
Revenue Per Share (ttm) | 1.76 ARS |
Quarterly Revenue Growth (yoy) | -2.10% |
Gross Profit (ttm) | 19.92B ARS |
EBITDA | 13.12B ARS |
Net Income Avi to Common (ttm) | 7.92B ARS |
Diluted EPS (ttm) | 349.97 |
Quarterly Earnings Growth (yoy) | 92.50% |
Balance Sheet
Total Cash (mrq) | 31.56B ARS |
Total Cash Per Share (mrq) | 2.13 ARS |
Total Debt (mrq) | 61.6B ARS |
Total Debt/Equity (mrq) | 1151.74 ARS |
Current Ratio (mrq) | 3.145 |
Book Value Per Share (mrq) | 0.360324 |
Cash Flow Statement
Operating Cash Flow (ttm) | 8.62B ARS |
Levered Free Cash Flow (ttm) | 7.95B ARS |
Profile of Amgen Inc.
Country | Argentina |
State | CA |
City | Thousand Oaks |
Address | One Amgen Center Drive |
ZIP | 91320-1799 |
Phone | 805 447 1000 |
Website | https://www.amgen.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 25200 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Q&A For Amgen Inc. Stock
What is a current AMGN.BA stock price?
Amgen Inc. AMGN.BA stock price today per share is 9375.5 ARS.
How to purchase Amgen Inc. stock?
You can buy AMGN.BA shares on the Buenos Aires exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amgen Inc.?
The stock symbol or ticker of Amgen Inc. is AMGN.BA.
Which industry does the Amgen Inc. company belong to?
The Amgen Inc. industry is Drug Manufacturers-General.
How many shares does Amgen Inc. have in circulation?
The max supply of Amgen Inc. shares is 13.26B.
What is Amgen Inc. Price to Earnings Ratio (PE Ratio)?
Amgen Inc. PE Ratio is 0.17340477 now.
What was Amgen Inc. earnings per share over the trailing 12 months (TTM)?
Amgen Inc. EPS is 54067.14 ARS over the trailing 12 months.
Which sector does the Amgen Inc. company belong to?
The Amgen Inc. sector is Healthcare.